Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 77

Cited In for PubMed (Select 12237282)


Hereditary Ovarian Cancer: Not Only BRCA 1 and 2 Genes.

Toss A, Tomasello C, Razzaboni E, Contu G, Grandi G, Cagnacci A, Schilder RJ, Cortesi L.

Biomed Res Int. 2015;2015:341723. Epub 2015 May 17. Review.


Breast cancer risks and risk prediction models.

Engel C, Fischer C.

Breast Care (Basel). 2015 Feb;10(1):7-12. doi: 10.1159/000376600. Review.


BRCA genetic screening in Middle Eastern and North African: mutational spectrum and founder BRCA1 mutation (c.798_799delTT) in North African.

Laraqui A, Uhrhammer N, Rhaffouli HE, Sekhsokh Y, Lahlou-Amine I, Bajjou T, Hilali F, El Baghdadi J, Al Bouzidi A, Bakri Y, Amzazi S, Bignon YJ.

Dis Markers. 2015;2015:194293. doi: 10.1155/2015/194293. Epub 2015 Feb 28. Review.


The fallopian tube: from back stage to center stage.

Greene MH, Mai PL.

Cancer Prev Res (Phila). 2015 May;8(5):339-41. doi: 10.1158/1940-6207.CAPR-15-0072. Epub 2015 Mar 23.


Pancreatic cancer early detection: expanding higher-risk group with clinical and metabolomics parameters.

Urayama S.

World J Gastroenterol. 2015 Feb 14;21(6):1707-17. doi: 10.3748/wjg.v21.i6.1707. Review.


Breast cancer in young women: special considerations in multidisciplinary care.

Reyna C, Lee MC.

J Multidiscip Healthc. 2014 Sep 29;7:419-29. doi: 10.2147/JMDH.S49994. eCollection 2014. Review.


Cancers associated with BRCA1 and BRCA2 mutations other than breast and ovarian.

Mersch J, Jackson MA, Park M, Nebgen D, Peterson SK, Singletary C, Arun BK, Litton JK.

Cancer. 2015 Jan 15;121(2):269-75. doi: 10.1002/cncr.29041. Epub 2014 Sep 15. Erratum in: Cancer. 2015 Jul 15;121(14):2474-5.


Therapeutic targeting of BRCA1-mutated breast cancers with agents that activate DNA repair.

Alli E, Solow-Cordero D, Casey SC, Ford JM.

Cancer Res. 2014 Nov 1;74(21):6205-15. doi: 10.1158/0008-5472.CAN-14-1716. Epub 2014 Sep 12.


Pancreatic ductal adenocarcinoma: risk factors, screening, and early detection.

Becker AE, Hernandez YG, Frucht H, Lucas AL.

World J Gastroenterol. 2014 Aug 28;20(32):11182-98. doi: 10.3748/wjg.v20.i32.11182. Review.


Endoscopic ultrasonography for surveillance of individuals at high risk for pancreatic cancer.

Lami G, Biagini MR, Galli A.

World J Gastrointest Endosc. 2014 Jul 16;6(7):272-85. doi: 10.4253/wjge.v6.i7.272. Review.


Tumors that mimic asbestos-related mesothelioma: time to consider a genetics-based tumor registry?

Kerger BD, James RC, Galbraith DA.

Front Genet. 2014 May 30;5:151. doi: 10.3389/fgene.2014.00151. eCollection 2014.


BRCA1 and estrogen/estrogen receptor in breast cancer: where they interact?

Wang L, Di LJ.

Int J Biol Sci. 2014 May 14;10(5):566-75. doi: 10.7150/ijbs.8579. eCollection 2014. Review.


Beyond Breast and Ovarian Cancers: PARP Inhibitors for BRCA Mutation-Associated and BRCA-Like Solid Tumors.

O'Sullivan CC, Moon DH, Kohn EC, Lee JM.

Front Oncol. 2014 Feb 28;4:42. doi: 10.3389/fonc.2014.00042. eCollection 2014. Review.


Screening and early detection of pancreatic cancer in high risk population.

Chang MC, Wong JM, Chang YT.

World J Gastroenterol. 2014 Mar 7;20(9):2358-64. doi: 10.3748/wjg.v20.i9.2358. Review.


Incidence of colorectal cancer in BRCA1 and BRCA2 mutation carriers: results from a follow-up study.

Phelan CM, Iqbal J, Lynch HT, Lubinski J, Gronwald J, Moller P, Ghadirian P, Foulkes WD, Armel S, Eisen A, Neuhausen SL, Senter L, Singer CF, Ainsworth P, Kim-Sing C, Tung N, Llacuachaqui M, Chornokur G, Ping S, Narod SA; Hereditary Breast Cancer Study Group.

Br J Cancer. 2014 Jan 21;110(2):530-4. doi: 10.1038/bjc.2013.741. Epub 2013 Nov 28.


Management of the asymptomatic BRCA mutation carrier.

Teller P, Kramer RK.

Appl Clin Genet. 2010 Nov 24;3:121-31. doi: 10.2147/TACG.S8882. Print 2010.


Examining the pathogenesis of breast cancer using a novel agent-based model of mammary ductal epithelium dynamics.

Chapa J, Bourgo RJ, Greene GL, Kulkarni S, An G.

PLoS One. 2013 May 21;8(5):e64091. doi: 10.1371/journal.pone.0064091. Print 2013.


Inhibiting the DNA damage response as a therapeutic manoeuvre in cancer.

Curtin NJ.

Br J Pharmacol. 2013 Aug;169(8):1745-65. doi: 10.1111/bph.12244. Review.

Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk